Compare Biogen Inc (BIIB) vs Salesforce Inc (CRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Salesforce Inc — how do they compare? Biogen Inc trades at $192.49 (market cap $28.34B), while Salesforce Inc trades at $169.62 (market cap $137.23B). The key difference: Salesforce Inc is far larger — about 4.8× Biogen Inc's market cap, and Salesforce Inc pays a 1.05% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | CRM | |
|---|---|---|
Market Cap | $28.34B | $137.23B |
Sector | Health | Technology |
52-Week High | $216.63 | $270.25 |
52-Week Low | $122.68 | $150.12 |
Enterprise Value | $30.62B | $167.28B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Salesforce (CRM) trades at $171.22, up 4.84% over 24 hours, with a bullish technical signal despite mixed momentum indicators. The company demonstrates strong fundamentals, including a 77.64% gross margin and consistent earnings beats, with Q1 2026 EPS of $3.88 exceeding the $3.13 estimate. Revenue grew to $37.90B in 2025, and operating cash flow reached $13.09B. Recent news highlights AI-driven growth potential, though the stock faces sector-wide volatility.
Outlook remains positive with a consensus price target of $235.90, implying 38% upside, supported by 73 buy ratings. Risks include competitive pressures in SaaS and macroeconomic sensitivity. AI adoption and strong cash flow generation present key opportunities for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →
